ArticleJournal of translational medicine2025
High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody-drug conjugate targeting Trop-2 is a promising therapeutic approach.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ionizing radiation promotes lung injury by inducing ferroptosis-driven senescence in epithelial cells via NCOA4-mediated ferritinophagy.Redox biology · 2026Article
- Anti-Trop2-Guided Liposomes Restore Methotrexate Sensitivity in Chemoresistant Gestational Trophoblastic Neoplasia.International journal of nanomedicine · 2026Article
- Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamous cell carcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundSeveral antibody-drug conjugates (ADC) targeting Trophoblast cell surface antigen 2 (Trop-2) have been developed, demonstrating significant therapeutic efficacy in triple-negative breast cancer and non-small cell lung cancer. However, the current expression of Trop-2 in pulmonary sarcomatoid carcinoma (PSC) and its clinical prognostic significance remains unclear. MATERIALS AND
methodsSurgical tissue specimens diagnosed with PSC from January 2015 to May 2023 were retrospectively collected to detect Trop-2 expression using immunohistochemistry. The semi-quantitative H-score was employed to evaluate Trop-2 expression (< 10 is 0, 10-40 is 1 + , 41-140 is 2+, and 141-300 is 3+). We evaluated Trop-2 expression in PSC patients, comparing expression levels between the carcinomatous component (CaC) and the sarcomatous component (SaC), and analyzed their associations with clinicopathological characteristics and prognosis.
resultsThirty-five PSC patients receiving curative surgical resection were enrolled. The median disease-free survival (DFS) in PSC patients was 15.7 (95% CI 7.0-24.4) months, while the median overall survival was not reached. Positive expression of Trop-2 was observed in 31 (88.6%) PSC patients, the frequencies of 1+, 2+, and 3+ were 28.6%, 42.9%, and 17.1%, respectively. In 25 PSC patients with both CaC and SaC, we found a difference in Trop-2 expression between the two components (CaC vs. SaC, 100% vs. 56.0%). The intratumoral heterogeneity (ITH) of Trop-2 expression was not associated with clinicopathologic features. Patients in the CaC+/SaC+ group demonstrated significantly poorer DFS compared to the CaC+/SaC- group (12.5 months vs. > 60.0 months, p = 0.045). Multivariate Cox regression analysis indicated that an ECOG score of ≥ 1 (p = 0.004), stage II (p = 0.032), and CaC+/SaC+ (p = 0.030) were independently associated with a shorter DFS.
conclusionThe level of Trop-2 expression was high in PSC patients, and there is ITH in its expression. Targeting Trop-2 therapies may be a promising treatment for patients with PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.